Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Aminacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.95 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.95 |
| ▸ | ACHE known ✓ | P22303 | 6/20 | 0.95 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.95 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.95 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.95 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.95 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.95 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.95 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.95 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.95 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.95 |
| ▸ | BCHE known ✓ | P06276 | 5/20 | 0.55 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.54 |
| ▸ | CACNB4 known ✓ | O00305 | 1/20 | 0.52 |
| ▸ | CACNA1A known ✓ | O00555 | 1/20 | 0.52 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 0.52 |
| ▸ | CACNG3 known ✓ | O60359 | 1/20 | 0.52 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.52 |
| ▸ | CACNA1H known ✓ | O95180 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminacrine SCHEMBL635597 | 1.00 | RAB9A (1.00) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL31237441 | 1.00 | RAB9A (1.00) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL6081733 | 0.97 | ALDH1A1 (1.00) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL30066711 | 0.97 | ALDH1A1 (1.00) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL1143741 | 0.97 | ALDH1A1 (1.00) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL29354393 | 0.97 | HSD17B10 (1.00) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL14999 | 0.97 | HSD17B10 (1.00) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL4907467 | 0.95 | HSD17B10 (0.95) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL14482032 | 0.95 | HSD17B10 (0.95) | RAB9AHSD17B10ALDH1A1KDM4EHPGD | |
| Aminacrine SCHEMBL18989123 | 0.95 | HSD17B10 (0.95) | RAB9AHSD17B10ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022117-A1 | RNAi-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2023-01-26 | — | — | US | claimed |
| EP-3263145-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS | BECTON DICKINSON CO (US) | 2021-01-20 | — | — | EP | claimed |
| US-9872941-B2 | Antimicrobial compositions and methods for locking catheters | BECTON, DICKINSON AND COMPANY (US) | 2018-01-23 | — | — | US | claimed |
| EP-3263145-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS | Becton, Dickinson and Company (US) | 2018-01-03 | — | — | EP | claimed |
| EP-1998825-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS | BECTON DICKINSON CO (US) | 2017-10-18 | — | — | EP | claimed |
| US-20170216493-A1 | Antimicrobial Compositions and Methods for Locking Catheters | BECTON, DICKINSON AND COMPANY | 2017-08-03 | — | — | US | claimed |
| US-9649411-B2 | Antimicrobial compositions and methods for locking catheters | BECTON, DICKINSON AND COMPANY (US) | 2017-05-16 | — | — | US | claimed |
| US-20160213818-A1 | Antimicrobial Compositions and Methods for Locking Catheters | BECTON, DICKINSON AND COMPANY | 2016-07-28 | — | — | US | claimed |
| US-9220725-B2 | Cationic latex as a carrier for bioactive ingredients and methods for making and using the same | MALLARD CREEK POLYMERS, INC. (US) | 2015-12-29 | — | — | US | claimed |
| CN-101426539-B | Antimicrobial compositions and methods of locking catheters | BECTON DICKINSON CO | 2013-06-12 | — | — | CN | claimed |
| WO-2008088394-A2 | ANIONIC LATEX AS A CARRIER FOR BIOACTIVE INGREDIENTS | MALLARD CREEK POLYMERS (US) | 2008-07-24 | — | — | WO | claimed |
| US-20080171804-A1 | Anionic latex as a carrier for bioactive ingredients and methods for making and using the same | MALLARD CREEK POLYMERS, INC. | 2008-07-17 | — | — | US | claimed |
| US-20080057049-A1 | Cationic latex as a carrier for bioactive ingredients and methods for making and using the same | MALLARD CREEK POLYMERS, INC. | 2008-03-06 | — | — | US | claimed |
| WO-2008024509-A2 | CATIONIC LATEX AS A CARRIER FOR BIOACTIVE INGREDIENTS AND METHODS FOR MAKING AND USING THE SAME | MALLARD CREEK POLYMERS, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2007100776-A2 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS | BECTON, DICKINSON AND COMPANY (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070202177-A1 | Antimicrobial Compositions and Methods for Locking Catheters | BECTON, DICKINSON AND COMPANY (US) | 2007-08-30 | — | — | US | claimed |
| US-20070149694-A1 | Cationic latex as a carrier for bioactive ingredients and methods for making and using the same | MALLARD CREEK POLYMERS, INC. | 2007-06-28 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |